GlassScriptPhysician profile
Steffanie Schwutke
NPI 1962410977
$3,850.80
in general payments reported to CMS, 2019-2025
34 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.93 · 2020: $112 · 2021: $335 · 2022: $457 · 2023: $988 · 2024: $702 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.17 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $366.64 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $308.74 | 2021-2025 | |
| Amgen INC. | $241.98 | 2021-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.48 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $196.79 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.55 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $161.70 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $157.94 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $148.87 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $140.29 | 2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $133.20 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $128.64 | 2022-2025 | Vpriv |
| Alk-Abello, INC | $124.27 | 2024-2025 | Ragwitek, Grastek, Odactra |
| Novo Nordisk INC | $120.16 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $75.29 | 2021 | |
| Abbott Laboratories | $67.15 | 2022-2025 | Id Now Instrument, Freestyle Libre 3 |
| Allergan, INC. | $64.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.02 | 2021-2025 | Jardiance |
| Organon LLC | $53.76 | 2025 | Nexplanon |
| Daiichi Sankyo INC. | $44.83 | 2024-2025 | Injectafer |
| Axsome Therapeutics, INC. | $43.71 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $37.81 | 2022-2023 | Quviviq |
| Ultragenyx Pharmaceutical INC. | $37.46 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $24.85 | 2022 | |
| Eisai INC. | $23.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.68 | 2022 | |
| Cepheid | $22.04 | 2025 | Genexpert |
| Ani Pharmaceuticals, INC. | $19.67 | 2025 | Purified Cortrophin Gel |
| Dexcom, INC. | $17.08 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $16.86 | 2024 | Gvoke Hypopen |
| Actelion Pharmaceuticals US, INC. | $16.19 | 2024 | Uptravi, Opsumit |
| Horizon Therapeutics Plc | $15.20 | 2021 | |
| Esperion Therapeutics, INC. | $15.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steffanie Schwutke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.